DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,747,459 | +1.1% | 11,074 | -2.1% | 1.57% | +9.8% |
| Q2 2023 | $2,716,946 | -5.5% | 11,308 | -0.8% | 1.43% | -10.2% |
| Q1 2023 | $2,875,802 | -5.3% | 11,398 | -0.3% | 1.59% | -9.0% |
| Q4 2022 | $3,036,052 | -0.8% | 11,428 | -3.4% | 1.75% | -8.6% |
| Q3 2022 | $3,059,000 | +1.3% | 11,833 | -0.6% | 1.92% | +5.4% |
| Q2 2022 | $3,019,000 | -16.4% | 11,908 | -3.2% | 1.82% | +3.5% |
| Q1 2022 | $3,610,000 | -11.4% | 12,308 | -0.6% | 1.76% | -5.4% |
| Q4 2021 | $4,074,000 | +7.2% | 12,383 | -0.8% | 1.86% | -3.6% |
| Q3 2021 | $3,800,000 | +13.4% | 12,483 | 0.0% | 1.93% | +14.8% |
| Q2 2021 | $3,350,000 | +19.2% | 12,483 | 0.0% | 1.68% | +12.1% |
| Q1 2021 | $2,810,000 | -0.3% | 12,483 | -1.6% | 1.50% | -4.8% |
| Q4 2020 | $2,818,000 | -6.2% | 12,685 | -9.1% | 1.57% | -15.4% |
| Q3 2020 | $3,004,000 | +20.0% | 13,950 | -1.5% | 1.86% | +6.3% |
| Q2 2020 | $2,504,000 | +27.4% | 14,160 | -0.2% | 1.75% | +11.2% |
| Q1 2020 | $1,965,000 | -12.6% | 14,194 | -3.1% | 1.57% | +6.3% |
| Q4 2019 | $2,248,000 | +4.0% | 14,644 | -2.2% | 1.48% | -3.5% |
| Q3 2019 | $2,162,000 | -2.2% | 14,970 | -3.2% | 1.53% | -1.7% |
| Q2 2019 | $2,210,000 | +7.9% | 15,460 | -0.3% | 1.56% | +3.1% |
| Q1 2019 | $2,048,000 | +25.0% | 15,510 | -2.4% | 1.51% | +12.4% |
| Q4 2018 | $1,639,000 | -5.1% | 15,895 | 0.0% | 1.35% | +6.7% |
| Q3 2018 | $1,727,000 | +7.6% | 15,895 | -2.2% | 1.26% | +0.5% |
| Q2 2018 | $1,605,000 | -0.7% | 16,260 | -1.5% | 1.26% | +4.1% |
| Q1 2018 | $1,616,000 | +4.1% | 16,500 | -1.3% | 1.21% | +10.3% |
| Q4 2017 | $1,552,000 | +5.0% | 16,725 | -2.9% | 1.09% | +5.6% |
| Q3 2017 | $1,478,000 | +4.4% | 17,225 | +2.7% | 1.04% | +0.1% |
| Q2 2017 | $1,416,000 | -2.1% | 16,775 | -0.8% | 1.03% | -3.5% |
| Q1 2017 | $1,447,000 | +10.0% | 16,915 | +0.1% | 1.07% | +7.3% |
| Q4 2016 | $1,315,000 | -1.0% | 16,890 | -0.3% | 1.00% | -1.9% |
| Q3 2016 | $1,328,000 | -22.6% | 16,940 | -0.3% | 1.02% | -22.5% |
| Q2 2016 | $1,716,000 | +6.4% | 16,990 | -0.1% | 1.31% | +6.0% |
| Q1 2016 | $1,613,000 | +3.2% | 17,000 | +1.0% | 1.24% | +1.8% |
| Q4 2015 | $1,563,000 | +7.7% | 16,825 | -1.2% | 1.22% | +4.3% |
| Q3 2015 | $1,451,000 | +0.1% | 17,025 | +0.6% | 1.17% | +7.2% |
| Q2 2015 | $1,449,000 | +32.4% | 16,925 | +31.3% | 1.09% | +35.4% |
| Q1 2015 | $1,094,000 | -14.3% | 12,890 | -13.4% | 0.80% | +0.1% |
| Q4 2014 | $1,276,000 | +12.8% | 14,890 | 0.0% | 0.80% | +6.6% |
| Q3 2014 | $1,131,000 | -3.5% | 14,890 | 0.0% | 0.75% | +0.9% |
| Q2 2014 | $1,172,000 | +4.5% | 14,890 | -0.3% | 0.75% | +1.6% |
| Q1 2014 | $1,121,000 | +0.6% | 14,940 | +3.5% | 0.73% | -1.6% |
| Q4 2013 | $1,114,000 | +11.0% | 14,430 | -0.3% | 0.75% | +6.7% |
| Q3 2013 | $1,004,000 | -99.9% | 14,480 | -50.3% | 0.70% | +3.2% |
| Q2 2013 | $923,837,000 | – | 29,160 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |